Literature DB >> 8972763

Quantitative ultrastructural study of afferent and efferent arterioles in IgA glomerulonephritis and benign nephrosclerosis.

Z Rázga1, B Iványi, N Zidar, D Ferluga, S Sonkodi, J Ormos.   

Abstract

Arteriolosclerosis frequently occurs in IgA nephritis (IgAN), and it is the hallmark of benign nephrosclerosis (BNS). The quantitative ultrastructure of juxtaglomerular arterioles is not known in these disorders. We examined afferent and efferent arterioles in renal biopsies from 25 adult patients with IgAN (hypertension at biopsy: 14 patients) and 9 patients with BNS. Six age-matched living renal transplant donors acted as controls. A systematic independent sample of profiles was obtained in thin sections taken at predetermined levels. The thickness of the media (myomedial cells plus the matrix) and the thickness of the medial matrix were estimated stereologically. From these estimates, the matrix/myomedia ratio was calculated. In IgAN with normotension or hypertension, the afferent media and its compartments did not exhibit significant thickening compared with the controls, whereas in BNS the afferent media and its layers were markedly and significantly thickened. The efferent media in IgAN and BNS displayed mild and significant thickening, with significant thickening of the matrix in BNS and IgAN with normotension. The matrix/myomedia ratio was not altered significantly in any group. The results indicate that the afferent arterioles are not the main sites of IgAN-related arteriolosclerosis, that arteriolosclerosis in IgAN and arteriolosclerosis in BNS are different lesions, and that increased efferent arteriolar thickness, demonstrated here for the first time in IgAN and BNS, might be a manifestation of angiotensin II-mediated autoregulatory efferent vasoconstriction exerted to maintain the glomerular filtration pressure.

Entities:  

Mesh:

Year:  1996        PMID: 8972763     DOI: 10.1007/bf00198343

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  50 in total

1.  Renal biopsies in hypertension.

Authors:  R H HEPTINSTALL
Journal:  Br Heart J       Date:  1954-04

2.  Proteinuria in IgA nephropathy.

Authors:  K Neelakantappa; G R Gallo; D S Baldwin
Journal:  Kidney Int       Date:  1988-03       Impact factor: 10.612

3.  Prognostic indicators in idiopathic IgA mesangial nephropathy.

Authors:  G D'Amico; L Minetti; C Ponticelli; G Fellin; F Ferrario; G Barbiano di Belgioioso; E Imbasciati; A Ragni; S Bertoli; G Fogazzi
Journal:  Q J Med       Date:  1986-04

Review 4.  Renal Parenchymal Hypertension: current concepts of pathogenesis and management.

Authors:  R A Preston; I Singer; M Epstein
Journal:  Arch Intern Med       Date:  1996-03-25

5.  Prognostic factors in mesangial IgA glomerulonephritis: an extensive study with univariate and multivariate analyses.

Authors:  E Alamartine; J C Sabatier; C Guerin; J M Berliet; F Berthoux
Journal:  Am J Kidney Dis       Date:  1991-07       Impact factor: 8.860

Review 6.  Prognostic pathologic markers in IgA nephropathy.

Authors:  G R Gallo; R Katafuchi; K Neelakantappa; D S Baldwin
Journal:  Am J Kidney Dis       Date:  1988-11       Impact factor: 8.860

7.  Clinical features of benign hypertensive nephrosclerosis at time of renal biopsy.

Authors:  A Innes; P A Johnston; A G Morgan; A M Davison; R P Burden
Journal:  Q J Med       Date:  1993-04

8.  Microvascular disease and the progression of IgA nephropathy.

Authors:  R Katafuchi; E Vamvakas; K Neelakantappa; D S Baldwin; G R Gallo
Journal:  Am J Kidney Dis       Date:  1990-01       Impact factor: 8.860

9.  Hyaline arteriolar nephrosclerosis. Immunofluorescence findings in the vascular lesions.

Authors:  R Valenzuela; P A Gogate; S D Deodhar; R W Gifford
Journal:  Lab Invest       Date:  1980-12       Impact factor: 5.662

10.  Hypertension-related aggravation of Iga nephropathy: a statistical approach.

Authors:  R Katafuchi; S Takebayashi; T Taguchi
Journal:  Clin Nephrol       Date:  1988-11       Impact factor: 0.975

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.